Tanya Revor, APRN
Family · Elizabethtown, KYNPI 1700396959
Payments from drug & device makers
Across 95 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$282
- Pfizer$235
- AstraZeneca$141
- Astellas Pharma US Inc$113
- Xeris Pharmaceuticals, Inc.$102
- Bayer$99
- plus $840 from 27 others
What the payments were for
- Food & beverage$1,69393%
- Education$1006%
- Entertainment$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $282 |
| Pfizer | 13 | $235 |
| AstraZeneca(2 entities) | 8 | $141 |
| Astellas Pharma US Inc | 2 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $102 |
| Bayer | 6 | $99 |
| Exact Sciences | 5 | $81 |
| Novo Nordisk | 4 | $71 |
| Medtronic | 2 | $50 |
| Amgen | 3 | $45 |
| Radius Health, Inc. | 2 | $41 |
| Edwards Lifesciences | 1 | $38 |
| Boston Scientific | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| BETA Bionics, Inc. | 1 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Seqirus USA Inc | 1 | $34 |
| Merck | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Pulmonx Corporation | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Optos, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Abbott | 1 | $16 |
| AbbVie | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
How this compares
$1,812 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $154,906 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $39,122 |
| MounjaroTirzepatide | 24 | $33,779 |
| JanuviaSitagliptin Phosphate | 30 | $31,182 |
| EliquisApixaban | 33 | $30,079 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $28,668 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $25,837 |
| TradjentaLinagliptin | 30 | $24,488 |
| JardianceEmpagliflozin | 21 | $23,629 |
| XareltoRivaroxaban | 18 | $14,855 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $9,641 |
| VascepaIcosapent Ethyl | 16 | $8,989 |
| MyrbetriqMirabegron | 14 | $8,977 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,426 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $71 | $154,906118 claims |
| Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat | $33 | $57,75863 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $282 | $46,54848 claims |
| MerckJanuvia, Janumet Xr | $34 | $35,57041 claims |
| Lilly USA, LLCMounjaro | $34 | $33,77924 claims |
| PfizerEliquis | $235 | $30,07933 claims |
| AstraZenecaBreztri Aerosphere | $141 | $25,83729 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $8,97714 claims |
| AbbVieLinzess, Synthroid | $15 | $8,76948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.
Other family in Elizabethtown
- Ashley SnellenElizabethtown$190K
- Gwendolynn ThomasElizabethtown$12K
- Bonnie HillLouisa$372K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.